Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Metals Royalty Co Inc.TMCR · Entity 5631 | Director | April 07, 2026 | April 08, 2026 |
| Niagen Bioscience, Inc.NAGE · Entity 6146 | Director | June 24, 2026 | June 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Metals Royalty Co Inc.
Report date April 07, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 37,500 |
Reported balance
Holding disclosure · report date 2026-04-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 37,500 F1: Represents restricted share units that vest in three equal annual installments commencing from November 10, 2025. |
| Common SharesSEC Table I · non-derivative | IndirectBy Impactreneur Capital Corp. | 135,375 |
Reported balance
Holding disclosure · report date 2026-04-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 135,375 F2: Represents shares held by Impactreneur Capital Corp. The Reporting Person is a control person of Impactreneur Capital Corp., and may be deemed to share voting, investment and dispositive power with respect to the securities held by Impactreneur Capital Corp. The Reporting Person disclaims beneficial ownership over such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2035-11-09 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The shares subject to this option shall vest and become exercisable in four equal annual installments commencing from November 10, 2025, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units that vest in three equal annual installments commencing from November 10, 2025.
F2: Represents shares held by Impactreneur Capital Corp. The Reporting Person is a control person of Impactreneur Capital Corp., and may be deemed to share voting, investment and dispositive power with respect to the securities held by Impactreneur Capital Corp. The Reporting Person disclaims beneficial ownership over such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3: The shares subject to this option shall vest and become exercisable in four equal annual installments commencing from November 10, 2025, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
Niagen Bioscience, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2036-06-23 | Direct | 31,746 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 31,746 · Balance 31,746 F1: Option vests 100% on June 24, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests 100% on June 24, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 21:56 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | GrantStock Option (right to buy) · Derivative | 31,746 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001942711-26-000001 · wk-form4_1782511002.xml · derivative · entry 1 Shahbazi Hamed · CIK 0001942711 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,746 Underlying: Common Stock · 31,746 shares Expires 2036-06-23 F1 · derivative.exercise_date: Option vests 100% on June 24, 2027. Read SEC document |
| June 24, 2025 Filed Jul 3, 2025 14:42 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.13 | $0.00 |
DisclosureSEC source: 0001628280-25-034160 · wk-form4_1751553733.xml · derivative · entry 1 Shahbazi Hamed · CIK 0001942711 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: Option vests 100% on June 24, 2026. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 21:42 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001628280-24-029647 · wk-form4_1719265316.xml · derivative · entry 1 Shahbazi Hamed · CIK 0001942711 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: Option vests 100% on June 20, 2025. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:29 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001628280-23-022539 · wk-form4_1686950964.xml · derivative · entry 1 Shahbazi Hamed · CIK 0001942711 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: Option vests 100% on June 15, 2024. Read SEC document |
| August 09, 2022 Filed Aug 13, 2022 01:11 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001628280-22-022759 · wf-form4_166035310008029.xml · derivative · entry 1 Shahbazi Hamed · CIK 0001942711 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-08-08 F1 · derivative.exercise_date: The option vests in three substantially equal annual installments beginning on August 9, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.